OncoMatch/Clinical Trials/NCT06411678
Application of 68GA-labeled CD73 Targeting Probe PET/CT Imaging in the Diagnosis of Breast Cancer
Is NCT06411678 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies 68GA-DOTA-dPNE for breast cancer.
Treatment: 68GA-DOTA-dPNE — The investigators plan to conduct a 68Ga-DOTA-dPNE PET/CT imaging study in breast cancer patients to observe the binding of the tracer to tumor lesions and evaluate CD73 expression. As part of the study design, a subset of patients will initially undergo dynamic PET/CT imaging to evaluate the safety profile and pharmacokinetic distribution of the radiotracer in vivo. Subsequently, static PET/CT imaging will be performed on additional patients to assess the diagnostic effectiveness of 68Ga-DOTA-dPNE. Imaging results will be correlated with relevant clinical indicators to evaluate the potential of this tracer in diagnosing breast cancer, guiding therapeutic decisions, and predicting responses to targeted therapies.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Prior therapy
Cannot have received: radiotherapy
No prior radiotherapy
Cannot have received: chemotherapy
No prior chemotherapy
Lab requirements
Kidney function
Severe renal dysfunction excluded
Liver function
Severe hepatic dysfunction excluded
Severe hepatic or renal dysfunction
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify